CD34 and Miyoshi myopathy: Similarly, Toor et al. reported the survival outcomes in MM patients (N = 104) undergoing a single transplant after conditioning with a conventional myeloablative regimen, busulphan, and cyclophosphamide and reported that higher CD34+ cell dose (> 4 × 106 cells/kg) infused were independently predictive of improved OS and PFS [12].